I need to read more of the filing to get the financial details. Let me work with what's provided, noting the balance sheet appears cut off.

LENZ Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 3, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Cash position: Cash and cash equivalents totaled $30,553 thousand as of September 30, 2026, up from $25,179 thousand at December 31, 2025.
  • Marketable securities: Marketable securities were $166,750 thousand as of September 30, 2026, compared to $267,168 thousand at December 31, 2025.
  • Total assets: Total assets were $209,749 thousand as of September 30, 2026, down from $305,876 thousand at December 31, 2025.
  • Inventory: Inventory was $4,760 thousand as of September 30, 2026, compared to $2,936 thousand at December 31, 2025.
  • Shares outstanding: As of October 28, 2026, 31,420,583 shares of common stock were outstanding.
  • Strategic reorganization: According to the filing, a strategic reorganization was announced in October 2026, with expected costs, timing, and anticipated benefits listed among the company's forward-looking statements.

LENZ Therapeutics Reports Q3 2026 Financial Position and Commercial Activity

LENZ Therapeutics, Inc. (NASDAQ:LENZ), a Delaware-incorporated company headquartered in Solana Beach, California, filed its quarterly report covering the period ended September 30, 2026. The company disclosed that total current assets stood at $206,897 thousand at quarter-end, compared to $301,412 thousand at December 31, 2025. The decline in total assets from $305,876 thousand to $209,749 thousand was driven primarily by a reduction in marketable securities from $267,168 thousand to $166,750 thousand over the same period.

According to the filing, cash and cash equivalents increased to $30,553 thousand from $25,179 thousand at year-end 2025, while accounts receivable, net, rose to $913 thousand from $329 thousand. Inventory increased to $4,760 thousand from $2,936 thousand, which the company attributed, in context, to commercial activity related to its product VIZZ. The filing identifies VIZZ as the company's commercialized product and references plans relating to its commercialization, including anticipated timing, geographic focus, and sales strategy, though the company notes these are forward-looking statements subject to risks and uncertainties.

The filing also references a strategic reorganization announced in October 2026. The company lists "the expected costs, timing and anticipated benefits of the strategic reorganization announced in October 2026" among its forward-looking statements, cautioning that actual results could differ materially. The company disclosed it qualifies as a non-accelerated filer, a smaller reporting company, and an emerging growth company under applicable SEC definitions.

What Was Disclosed

LENZ Therapeutics filed its Form 10-Q for the quarter ended September 30, 2026, disclosing a balance sheet showing $209,749 thousand in total assets, a reduction in marketable securities, increased inventory, and 31,420,583 shares outstanding as of October 28, 2026.